Cite
Kats D, Ricker CA, Berlow NE, et al. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget. 2019;10(60):6403-6417doi: 10.18632/oncotarget.27237.
Kats, D., Ricker, C. A., Berlow, N. E., Noblet, B., Nicolle, D., Mevel, K., Branchereau, S., Judde, J. G., Stiverson, C. D., Stiverson, C. L., Svalina, M. N., Settelmeyer, T., Matlock, K., Lathara, M., Mussini, C., Geller, J. I., Noakes, C., Sloma, I., Bharathy, N., Cairo, S., & Keller, C. (2019). Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget, 10(60), 6403-6417. https://doi.org/10.18632/oncotarget.27237
Kats, Dina, et al. "Volasertib preclinical activity in high-risk hepatoblastoma." Oncotarget vol. 10,60 (2019): 6403-6417. doi: https://doi.org/10.18632/oncotarget.27237
Kats D, Ricker CA, Berlow NE, Noblet B, Nicolle D, Mevel K, Branchereau S, Judde JG, Stiverson CD, Stiverson CL, Svalina MN, Settelmeyer T, Matlock K, Lathara M, Mussini C, Geller JI, Noakes C, Sloma I, Bharathy N, Cairo S, Keller C. Volasertib preclinical activity in high-risk hepatoblastoma. Oncotarget. 2019 Nov 05;10(60):6403-6417. doi: 10.18632/oncotarget.27237. eCollection 2019 Nov 05. PMID: 31741706; PMCID: PMC6849653.
Copy
Download .nbib